Blood Culture Tests Market Share

APAC Market Forecast

The blood culture tests market in Asia Pacific is estimated to cross more than USD 6.20 billion by the end of 2036. Blood culture is currently the accepted method of diagnosis for possible bacteremia in the region. If bacteremia is suspected in a majority of high-income countries, blood cultures are often provided to patients with fever. Nevertheless, when working under resource constraints, physicians may decide to give patients direct treatment due to a lack of or limited laboratory capacities. In the present era of increasing antibiotic resistance, particularly in South Asia, blood cultures are becoming a more important tool to help identify the best course of therapy and promote effective management.

North American Market Statistics

The blood culture tests market in the North American region is set to grow substantially by reaching growth rate of USD 5.91 billion by the end of 2036. Rising demand for antimicrobial susceptibility testing awaits the blood culture testing market in the region. The most effective treatment for patients with bloodstream infections depends largely on the rapid identification of blood culture isolates and the conclusions of his AST. The importance of blood cultures is highlighted in the area by the fact that empiric antibiotic dosing is often inappropriate, leading to increased morbidity and mortality, prolonged hospital stays, and associated healthcare costs. Additionally, in September 2023, FDA issued a regulation entitled “Antibiotic Susceptibility Testing System Devices – Updates to Breakpoints in Device Labeling,” effective immediately.